Regístrese gratis y obtenga acceso ilimitado a nuestra extensa biblioteca de elearning
Gane puntos CME y realice un seguimiento de su actividad de aprendizaje con cientos de horas de educación médica continua.
Compartir :

Single agent activity of IOI in solid tumours: Renal

This module focuses on the immunogenicity of renal cancer and provides an overview of the current clinical research in immunotherapy for this tumour type.

This module is part of a course; 15 modules providing an up to date resource for medical professionals who seek to understand the latest research, advances in technology and future directions of immuno-oncology.

Published February 2019.

Single agent activity of IOI in solid tumours: Renal
0 CME Points

Público destinatarios

This module is aimed at medical professionals interested in the field of immuno-oncology.

Objetivos educativos

By the end of this module you will be able to:

  • Understand the immunogenic nature of renal cancer
  • Describe the immune response of renal cancer observed in clinical trials
  • Be aware of the future directions of research, challenges and gaps in knowledge

Requisitos del sistema

This module requires the learner to have a good, stable internet connection and can run on Internet Explorer 7 and above, Mozilla Firefox, Google Chrome and Opera on either Windows or MacOS. Flash Add-on is also required to run this module.

If you are viewing this module on an iPad (through a browser), please download the free Articulate Mobile Player beforehand. Other tablet devices may not be compatible - please check for Flash compatibility.

If you are experiencing technical difficulties, please contact and we will get back to you as soon as possible.

Política de divulgación

ecancer and everyone involved in the development of this module has no actual or potential conflict of interest whatsoever which impinges on the making, peer reviewing and dissemination of this e-learning module which was made possible through an unrestricted educational grant from the Bristol-Myers Squibb Foundation and AbbVie Inc.

Both the BMS Foundation and AbbVie Inc. have had no input in the creation of the e-learning materials including the process of selecting speakers.

For more information, please email


Production of this module was funded by an unrestricted grant from Bristol-Myers Squibb Foundation and AbbVie Inc.